Rankings
▼
Calendar
VTRS Q3 2024 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena
VTRS
Viatris Inc.
$17B
Q3 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$3.8B
-4.8% YoY
Gross Profit
$1.5B
38.9% margin
Operating Income
$226M
6.0% margin
Net Income
$95M
2.5% margin
EPS (Diluted)
$0.08
QoQ Revenue Growth
-1.2%
Cash Flow
Operating Cash Flow
$827M
Free Cash Flow
$741M
Stock-Based Comp.
$32M
Balance Sheet
Total Assets
$44.8B
Total Liabilities
$25.0B
Stockholders' Equity
$19.8B
Cash & Equivalents
$1.9B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.8B
$3.9B
-4.8%
Gross Profit
$1.5B
$1.7B
-13.7%
Operating Income
$226M
$452M
-50.0%
Net Income
$95M
$332M
-71.4%
Revenue Segments
Brands
$2.4B
63%
Generics
$1.4B
37%
Geographic Segments
Developed Markets Segment
$2.3B
61%
Greater China Segment
$562M
15%
Emerging Markets Segment
$533M
14%
Japan, Australia and New Zealand Segment
$344M
9%
← FY 2024
All Quarters
Q4 2024 →